medigraphic.com
ISSN 2221-2434 (Electronic)

2021, Number 4

<< Back Next >>

Finlay 2021; 11 (4)

Identification of thrombosis risk in patients with suffering cancer conditions undergoing chemotherapy

Jiménez AM, Fernández ÁJD, Vasallo DAL, Calzada UD

Language: Spanish
References: 17
Page: 352-358
PDF size: 248.95 Kb.


ABSTRACT

Background: there is an established relationship between cancer and the appearance and development of thromboembolic disease. It is necessary to identify patients with an increased risk of venous thromboembolism using predictive scales to individualize the risk.
Objective: to identify the risk of thrombosis in patients with suffering cancer conditions undergoing chemotherapy.
Method: a series of cases descriptive cross-sectional study, treated at the Clinical Oncology Service of the Dr. Gustavo Aldereguía Lima University General Hospital, Cienfuegos, from June the 1st, 2020 to April 30th, 2021. The information was obtained from the clinical record and a data collection model. The variables analyzed were: age, sex, site of the primary tumor, platelet count prior to chemotherapy, serum hemoglobin levels, erythropoietin use, leukocyte count prior to chemotherapy, and body mass index. The data obtained were processed using the SPSS version 21 statistical program and the results are presented in tables using absolute numbers and percentages.
Results: the most frequent age group was 60 years old and over with 77 patients (51.3 %), 45 (30 %) male. The application of the Khorana score marked a relevant percentage (26 %) of patients with intermediate and high risk of thrombosis.
Conclusions: the research shows a mostly aged adult population, with risk factors for thrombosis related to the patient, oncological disease and systemic treatments.


REFERENCES

  1. Organización Mundial de la Salud 2020. Cáncer. Datos y Cifras[Internet]. Washington:OMS;2020[citado 23 Jun 2021]. Disponible en: Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/cancer .

  2. Sack GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine. 1977;56(1):1-37.

  3. Epstein AS, Soff GA, Capanu M, Crosbie C, Shah MA, Kelsen DP, et al. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer. 2012;118(12):3053-61.

  4. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-64.

  5. Falanga A, Russo L, Verzeroli C. Mechanisms of thrombosis in cancer. Thromb Res. 2013;131(Suppl. 1):S59-S62.

  6. Martínez P, Antonio MA, Borrega P, Marín G, Salgado M, Navarro LM, et al. II Consenso SEOM sobre la Enfermedad Tromboembólica en Pacientes con Cáncer[Internet]. Barcelona:Sociedad Española de Oncología Médica;2013[citado 26 May 2020]. Disponible en: Disponible en: https://www.seom.org/seomcms/images/stories/recursos/II_Consenso_SEOM_enf_tromboembolica_cancer.pdf .

  7. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy associated thrombosis. Blood. 2008;111(10):4902-7.

  8. Bustillo MJ, López D, Feito T, García F, Álvarez Y. Trombosis venosa profunda en adultos mayores con cáncer. Rev Cubana Angiol Cir Vasc[Internet]. 2015[citado 12 May 2020];16(1):[aprox. 10p.]. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1682-00372015000100003.

  9. Kourlaba G, Relakis J, Mylonas C, Kapaki V, Kontodimas S, Holm MV, et al. The humanistic and economic burden of venous thromboembolism in cancer patients: a systematic review. Blood Coagul Fibrinolysis. 2015;26(1):13-31.

  10. Alfonso A, Inguanzo IB. Síndrome de Trousseau como manifestación de neoplasia maligna. Invest Med Quir[Internet]. 2020[citado 23 May 2021];12(1)[aprox. 10p.]. Disponible en: https://www.medigraphic.com/pdfs/invme d/cmq-2020/cmq201n.pdf.

  11. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466-73.

  12. Ugarte G, Otero R, Ferrer M, Morillo R, Elías T, Jara L. Predictive Khorana's model in patients with venous thromboembolic disease and cancer. Med Clin (Barc). 2013;141(11):479-81.

  13. Parliamentary Thrombosis Group. Venous Thromboembolism in Cancer: cancer chemotherapy and clots[Internet]. London:Parliamentary Thrombosis Group;2015[citado 28 Oct 2020]. Disponible en: Disponible en: https://www.anticoagulationuk.org/admin/resources/downloads/apptg-cancer-chemotherapy-and-clots-oct-15.pdf .

  14. Aronés A, Carrasco A, Delgado C, López M. Incidencia de enfermedad tromboembólica en neoplasias malignas en cuatro hospitales de Lima. Rev Soc Perú Med Inter[Internet]. 2002[citado 10 Jun 2020];15(2):[aprox. 15p.]. Disponible en: https://sisbib.unmsm.edu.pe/bvrevistas/spmi/v15n2/inci_enfer.htm.

  15. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model of chemotherapy- associated thrombosis. Blood. 2008;111(10):4902-7.

  16. Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer- associated thrombosis: risk factor, biomarkers and e risk score. Thromb Res. 2010;125(Suppl. 2):1-7.

  17. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy- associated venous thromboembolism in a prospective observational study. Cancer. 2005; 104(12):2822-9.




2020     |     www.medigraphic.com